ClinicalTrials.gg
Active, not recruitingNCT05732805OCTAVAUpdated Feb 27, 2025

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

A Phase 3 interventional study of BCD-217 and BCD-100 in Melanoma, Melanoma (Skin) and Melanoma Stage III, sponsored by Biocad. Active, not recruiting at 63 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Aug 2022, registered Feb 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Melanoma by Biocad — none open to participants now, 6 under way, 4 of them phase 3. Melanoma · Biocad.

Planned enrollment
5th of 12
270 · median 129
Started
2022
with 2 others
Phase 3
5 of 12
none open now
Registered
7th of 12
by date

Among the 12 studies in Melanoma by Biocad, this one is the 5th largest by planned enrollment, is one of 3 that started in 2022, is one of 5 in phase 3, and was the 7th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 12 studies in Melanoma by Biocad is open now. The open studies under Melanoma, anywhere →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Melanoma by Biocad as a file.
02

Study summary

The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with unresectable or metastatic melanoma.

Read the detailed description

This study is designed as a phase III, randomized, double-blind, placebo-controlled study.

After the stratification procedure, subjects are randomized in a 1:1 ratio into 2 groups:

  • BCD-217 + placebo (4 doses) → prolgolimab (BCD-217 group)
  • Prolgolimab + placebo (4 doses) → prolgolimab (BCD-100 monotherapy group)
03

Conditions studied

  • Melanoma
  • Melanoma (Skin)
  • Melanoma Stage III
  • Melanoma Stage IV
  • Melanoma Unresectable
  • Melanoma Metastatic
  • Melanoma Advanced

Browse trials for

Keywords

  • PD-1
  • CTLA-4
  • prolgolimab
  • nurulimab
  • immunotherapy
  • checkpoint inhibitors
  • CPI
  • programm death
  • cytotoxic T-lymphocyte-associated protein
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and the subject's ability to comply with the requirements of the clinical study protocol;
  2. Age ≥18 years at the time of signing the informed consent form;
  3. confirmed melanoma (with available documented evidence of relevant investigations);
  4. Untreated unresectable stage III melanoma or untreated (stage IV) melanoma;
  5. Available blocks for histological examination and/or the subject's consent to undergo ;
  6. Consent to the evaluation of the status and BRAF V600 mutation status at a central laboratory;
  7. score 0-1;
  8. of at least 12 weeks ;
  9. Measurable target tumor lesions (at least 1 lesion) according to 1.1 criteria , confirmed by central independent reviewer;
  10. In subjects of , willingness to use reliable measures throughout the study, from the signing of the informed consent form and for additional 24 weeks after the administration of the last dose of the product.

Exclusion criteria

Exclusion Criteria:

  1. Indications for radical (surgical, radiation) therapy;
  2. A history of previous systemic antitumor therapy for unresectable or melanoma ;
  3. Prior therapy with (e.g., anti-CTLA-4 and/or anti-PD-1/PD-L1/PD-L2 products);
  4. Prior therapy with BRAF and MEK protein kinase inhibitors;
  5. Use of immunostimulants, monoclonal antibodies and/or colony-stimulating factors within less than 4 weeks prior to randomization in the study;
  6. Ocular melanoma;
  7. Mucosal melanoma;
  8. ;
  9. Impossibility to determine PD-L1 status and/or BRAF status;
  10. Subjects with severe comorbidities, life-threatening acute complications of the primary disease (including massive pleural, pericardial, or peritoneal effusions requiring intervention , pulmonary lymphangitis, bleeding, or organ perforation) at the time of signing the form;
  11. Ongoing concomitant diseases at the time of screening, which increase the risk of severe adverse events during the administration of the study therapy:

    • stable angina, functional class III-IV;
    • unstable angina or a history of myocardial infarction within less than 6 months prior to signing the informed consent form;
    • moderate to severe heart failure (classes III and IV according to classification);
    • uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg) ;
    • a history of atopic asthma , angioedema;
    • respiratory failure (moderate to severe), grade 3 or 4 ;
    • any other concomitant diseases (including, but not limited to, metabolic, hematological, renal, hepatic, pulmonary, neurological, endocrine, cardiac, infectious, gastrointestinal disorders), which expose the subject to an unacceptable risk during the study therapy;
  12. Known or suspected systemic diseases (including, but not limited to, systemic lupus erythematosus, Crohn's disease, nonspecific ulcerative colitis, systemic scleroderma, inflammatory myopathy, mixed connective tissue disease, overlap syndrome, etc.) ;
  13. History of interstitial pulmonary disease or pneumonitis requiring systemic ;
  14. The need for glucocorticoid therapy (at >10 mg/day prednisolone equivalent doses) or any other drugs with effects within 14 days prior to randomization;
  15. Hematologic abnormalities :

    • neutrophils \<1.5×109/L;
    • \<100×109/L;
    • \<90 g/L;
  16. Renal impairment: creatinine ≥2.5×;
  17. Hepatic impairment :

    • total ≥3×ULN (except for subjects with Gilbert's syndrome, in whom bilirubin levels should not exceed 50 μmol/L),
    • AP, or ALT ≥2.5×ULN (≥5×ULN in case of subjects with liver metastases);
  18. Any antitumor treatment within less than 4 weeks or surgery within less than 28 days prior to randomization within the study;
  19. History of oncological disease, except for radically treated diseases with remission for over 5 years prior randomization in this study ;
  20. Conditions limiting the subject's ability to comply with the Protocol requirements (in the Investigator's opinion );
  21. Participation in other clinical studies within less than 30 days prior to randomization and during this clinical study ;
  22. Acute infections or activation of chronic infectious diseases or systemic antibacterial therapy within less than 28 days prior to randomization;
  23. Active , active (confirmed by PCR), active syphilis, -infection, currently or previously ;
  24. Impossibility to administer the product intravenously;
  25. Impossibility to administer intravenous contrast agents (including due to to contrast media);
  26. Hypersensitivity to any of the components of BCD-100 or BCD-217;
  27. A history of hypersensitivity to monoclonal antibody products;
  28. Pregnancy or breastfeeding.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    BCD-217 (nurulimab + prolgolimab)

    BCD-217 followed by prolgolimab 1 mg/kg monotherapy.

    Biological: BCD-217 · Biological: BCD-100 · Biological: Placebo

  • Active comparator
    BCD-100 (prolgolimab)

    Prolgolimab monotherapy.

    Biological: BCD-100 · Biological: Placebo

Interventions

  • BiologicalAnti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217Studies of Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).

    Also known as: nurulimab+prolgolimab

  • BiologicalProlgolimabStudies of ProlgolimabProlgolimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).

    Also known as: prolgolimab, Forteca

  • BiologicalPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Time frame: 24 months

Secondary outcomes

  1. Overall survival

    Time frame: 24 months

  2. Overall response rate (partial response + complete response rate)

    Time frame: 24 months

  3. Disease control rate (stable disease + partial response + complete response rate)

    Time frame: 24 months

  4. Time to response

    Time frame: 24 months

  5. Duration of response

    Time frame: 24 months

  6. The proportion of subjects experiencing adverse events related to study therapy

    Time frame: 24 months

  7. The proportion of subjects experiencing any grade 3 or higher adverse events

    Time frame: 24 months

  8. The proportion of subjects with SAEs

    Time frame: 24 months

  9. The proportion of subjects with immune-related adverse events of any severity

    Time frame: 24 months

  10. The proportion of subjects with severe immune-related adverse events

    Time frame: 24 months

  11. The proportion of subjects requiring treatment discontinuation due to AEs

    Time frame: 24 months

  12. The proportion of BAb and NAb positive subjects

    Time frame: 24 months

  13. Ctrough (plasma concentration of anti-PD-1/CTLA-4 monoclonal antibody measured at the end of the dosing interval before the next dose)

    Time frame: 24 months

07

Study locations

63 sites
  • Healthcare Institution "Bobruisk Interdistrict Oncological Dispensary"
    Babruysk, Belarus
  • Healthcare Institution "Brest Regional Oncological Dispensary"
    Brest, Belarus
  • Health Institution "Gomel Regional Clinical Oncology Center"
    Gomel, Belarus
  • Health care institution "Grodno University Clinic"
    Grodno, Belarus
  • State Institution "Republican Scientific and Practical Center of Oncology and Medical Radiology named after A.I. N.N. Alexandrov"
    Lesnoy, Belarus
  • Healthcare Institution "Minsk City Clinical Cancer Center"
    Minsk, 220013, Belarus
  • State Institution "Mogilev Regional Oncological Dispensary"
    Mogilev, Belarus
  • Healthcare Institution "Vitebsk Regional Clinical Oncology Center"
    Vitebsk, Belarus
  • Fortis Hospital
    Faridabad, India
  • Kasturba Medical College and Hospital
    Mangalore, India
  • TATA Memorial Hospital
    Mumbai, India
  • HealthCare Global Enterprises Ltd, NCHRI Cancer Center
    Nagpur, India
  • HealthCare Global Enterprises Ltd Manavata cancer Centre
    Nashik, India
  • Sankalp Superspeciality Hospital
    Nashik, India
  • All India Institute of Medical Science
    New Delhi, India
  • Deenanath Mangeshkar Hospital & Research Center
    Pune, India
  • PDEAS Ayurved Rugnalaya & Steriling Multispeciality Hospital
    Pune, India
  • Horizon Mulitispeciality Hospital
    Sangli, India
  • Shalby Hospital
    Surat, India
  • Kiran Multispeciality hospital &Research
    Sūrat, India
  • Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine
    Chelyabinsk, Chelyabinsk Oblast 454087, Russian Federation
  • LLC "New Clinic"
    Pyatigorsk, Stavropol Krai 357500, Russian Federation
  • Arkhangelsk Clinical Oncology Dispensary
    Arkhangel'sk, Russian Federation
  • Regional State Budgetary Institution of Health Care "Altai Regional Oncological Dispensary"
    Barnaul, Russian Federation
  • Limited Liability Company "EVIMED"
    Chelyabinsk, Russian Federation
  • Private healthcare institution "Clinical hospital "RZD-Medicine" of the city of Chelyabinsk"
    Chelyabinsk, Russian Federation
  • State budgetary healthcare institution Leningrad Regional Clinical Hospital
    Gatchina, Russian Federation
  • State Autonomous Health Institution "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal"
    Kazan, Russian Federation
  • State budgetary health care institution "Kuzbass clinical oncological dispensary named after M.S. Rappoport"
    Kemerovo, Russian Federation
  • Regional Goverment Budgetary Healthcare State "Kostroma Oncology Center"
    Kostroma, 156005, Russian Federation
  • State Budgetary Institution of Healthcare "Leningrad Regional Clinical Oncological Dispensary named after V.I. L.D. Romana"
    Kuz'molovskiy, Russian Federation
  • "Russian Cancer Research Center named after N.N. Blokhin "of the Ministry of Health of the Russian Federation
    Moscow, Russian Federation
  • Branch of Hadassah Medical LTD Limited Liability Company
    Moscow, Russian Federation
  • Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
    Moscow, Russian Federation
  • Joint Stock Company "K31 City"
    Moscow, Russian Federation
  • JSC "Medsi Group"
    Moscow, Russian Federation
  • Moscow City Oncology Hospital No. 62
    Moscow, Russian Federation
  • State budgetary health care institution of the city of Moscow "City Clinical Oncology Hospital No. 1 of the Department of Health of the City of Moscow"
    Moscow, Russian Federation
  • State Budgetary Institution of Healthcare of the City of Moscow "Moscow Multidisciplinary Clinical Center "Kommunarka" of the Department of Health of the City of Moscow"
    Moscow, Russian Federation
  • Nizhny Novgorod Region State Budgetary Healthcare Facility "Clinical Diagnostics Center"
    Nizhny Novgorod, 603006, Russian Federation
  • LLC "DobroMed"
    Novosibirsk, Russian Federation
  • State Budgetary Healthcare Institution "Novosibirsk Regional Clinical Oncology Center" of the Novosibirsk Region
    Novosibirsk, Russian Federation
  • Federal State Budgetary Institution "National Medical Research Center for Radiology" of the Ministry of Health of the Russian Federation
    Obninsk, Russian Federation
  • Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Center"
    Omsk, Russian Federation
  • Federal State Budgetary Institution "National Medical Research Center of Oncology named after N.N. Petrov" of the Ministry of Health of the Russian Federation (FSBI "N.N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of Ru
    Pesochnyy, Russian Federation
  • LLC "Clinical Trials"
    Saint Petersburg, 188663, Russian Federation
  • JSC "Modern Medical Technologies"
    Saint Petersburg, 190013, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State University"
    Saint Petersburg, Russian Federation
  • Federal State Budgetary Health Institution St. Petersburg Clinical Hospital of the Russian Academy of Sciences
    Saint Petersburg, Russian Federation
  • Limited Liability Company "EuroCityClinic"
    Saint Petersburg, Russian Federation
  • Limited Liability Company "Oncological Research Center"
    Saint Petersburg, Russian Federation
  • Limited Liability Company "Stepmed Clinic"
    Saint Petersburg, Russian Federation
  • Limited Liability Company "Strategic Medical Systems"
    Saint Petersburg, Russian Federation
  • LLC "AV medical group"
    Saint Petersburg, Russian Federation
  • N.N. Petrov National Medicine Research Center of oncology
    Saint Petersburg, Russian Federation
  • Private Medical Institution Evromedservis
    Saint Petersburg, Russian Federation
  • Private institution educational organization of higher education "Medical University "Reaviz"
    Samara, Russian Federation
  • State budgetary health care institution "St. Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological)"
    Sankt Petersburg, Russian Federation
  • Federal State Educational Institution of Higher Professional Education "Mordovia State University N.P. Ogareva "
    Saransk, Russian Federation
  • Oncology Dispensary 2
    Sochi, 354057, Russian Federation
  • City Hospital #40, Kurortny district
    St. Petersburg, Russian Federation
  • State Health Care Institution "Volgograd Regional Clinical Oncology Dispensary № 1"
    Volgograd, Russian Federation
  • State Regional Budgetary Healthcare Institution "Regional Clinical Oncology Hospital" of the Yaroslavl Region
    Yaroslavl, 150054, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jun 2024, 22 months.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 22 months is below that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Feb 17, 2023
StartActual
Aug 2, 2022
Primary completionActual
Jun 20, 2024
CompletionEst.
Jul 2025
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05732805
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Feb 17, 2023
Start date
Aug 2, 2022
Primary completion
Jun 20, 2024
Completion
Jul 2025 (estimated)
Last update
Feb 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217

Start the discussion